S

Clinical Trials

As a Center of Research Translation, the Center for Musculoskeletal Research, URMC Orthopaedics and Rehabilitation, and UR Rheumatology are committed to increasing the diversity and efficacy of treatments and procedures available to our patients from the Rochester, NY region. We conduct state-of-the-art translational studies to better understand disease processes and clinical trials in multi-site efforts that are national in scope.

URMC is one of the first institutions nationwide with funding from the National Institutes of Health to establish the University of Rochester Clinical and Translational Science Institute (CTSI). The CTSI is to lead the emerging field of clinical and translational research to more quickly advance treatments to patients. We are also developing educational programs to train clinicians and biomedical scientists in the conduct of translational research and clinical trials.

Read about our clinical trials below.

Clinical Trials

Principal Investigator

RSRB#/WIRB#

Official Title Sponsor

ClinicalTrials.gov#

 

Anolik

Pending

A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 in Subjects with Systemic Lupus Erythematosus Celgene Corporation NCT02185040

Anolik

24715

A Partially Blinded, Randomized Multi-Center, Phase IV Trial to Evaluate Mechamism of Action of Anti-TNF Agents in Rheumatoid Arthritis (ARA06) NIH NIAID Autoimmunity Centers of Excellence NCT00837434

Anandarajah

20101481

A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Paraellel-Group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Subjects with Active Psoriatic Arthritis Celgene Corporation NCT01212757

Anandarajah

20131480

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of The Efficacy and Safety of 2 Doses of Tofacitinib (Cp-690,550) or Adalimumab in Subjects with Active Psoriatic Arthritis Pfizer, Inc. NCT01877668

Coca

39964

A Randomized, Double-Blind, Placebo-controlled Phase II Clinical Trial of Baminercept, a Lymphotoxin-beta Receptor Fusion Protein, for the Treatment of Primary Sjögren's Syndrome (ASJ02) NIH NIAID NCT01552681

Looney

49397

T and B Cell Responses Across Autoimmune Diseases (SRA01) NIH NIAID Autoimmunity Centers of Excellence NTC01947036

Looney

48772

An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients with Stable, Quiescent Systemic Lupus Erythematosus (SLE) NIH NIAID Autoimmunity Centers of Excellence NCT01946880

Ritchlin

55799

A Randomized, Double-Blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-1 Amgen, Inc. NCT02029495

Ritchlin

39346

A Randomized, Double-blinded, Placebot-controlled Multiple-dose Study with an Open Label Extension to Evaluate the Safety and Efficacy of AMG 827 in Subjects with Psoriatic Arthritis Amgen, Inc. NCT01516957

Ritchlin

53086

DC-STAMP and TRAF3: Regulators of Osteoclastogenesis and Biomarkers in Psoriatic Arthritis NIH NCATS CTSA NCT02413749

Ritchlin

53131

Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients Rheumatology Research Foundation NCT2413801

Ritchlin

13959

Microarray Analysis of Peripheral Blood and Tissues of Patients with Immune Mediated Inflammatory Diseases Centocor, Inc. NCT00462072

Ritchlin

32368

Dendritic Cell-Specific Transmembrane Protein

(DC-STAMP) as a Severity and Response Biomarker in Psoriatic Arthritis

National Psoriasis Foundation NCT01123265

Ritchlin

35995

The Morphologic and Functional Relationship Between the Draining PLN and Synovial Inflammation in the Knee Joints of RA Patients Before and After Anti-TNF or B Cell Depletion Therapy NIH NIAID P01 NCT01083563

Ritchlin

27553

The Effect of Certolizumab on Lower Extremity Lymph Flow in Rheumatoid Arthritis UCB, Inc. NCT01098201

Ritchlin

39665

Prospective Validation of Soluble Biomarkers as Predictors of Structural Damage in Rheumatoid Arthritis Canadian Research and Education in Arthritis NCT01476956

Schwarz

15198

Vascular CT Assessment of Structural Autograft and Allograft Healing NIH NIAMS P50 CORT NCT00594776

White/Looney

31281

A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to DS20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) NIH NIAID Autoimmunity Centers of Excellence NCT01086540

Please also see a list of our Sponsored Clinical Studies